PHARMACEUTICAL RESEARCH ASSOCIATES DENMARK ApS: Financial statements 2020
CVR: 33242840
Source: annual report 2020, Danish Business Authority
01/01/2020 – 31/12/2020
PHARMACEUTICAL RESEARCH ASSOCIATES DENMARK ApS (CVR 33242840) has filed annual accounts for 2020. In 2020, the company reported a gross profit of DKK 34,745,603 and a net result of DKK 2,056,895 compared with DKK 1,584,074 the year before. That is an increase of 28.9% compared with the year before. Equity in the 2020 report amounted to DKK 8,501,030. The solvency ratio was 60.8%. The company had 37 employees in the financial year.
- Gross Profit
- DKK 34,745,603
- Profit/Loss
- DKK 2,056,895
- Equity
- DKK 8,501,030
- Total Assets
- DKK 13,971,073
- Employees
- 37
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2020 | - | 34.7M | 2.1M | 8.5M | 37 |
| 2019 | - | 27M | 1.6M | 6.4M | 34 |
| 2018 | - | 27.8M | 1.4M | 4.9M | 29 |
| 2017 | - | 25.8M | 1M | 3.5M | 32 |
| 2016 | - | 23.6M | 1.2M | 2.5M | - |
Official annual report
How creditworthy is PHARMACEUTICAL RESEARCH ASSOCIATES DENMARK ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2020
PHARMACEUTICAL RESEARCH ASSOCIATES DENMARK ApS has published its annual report for 2019. Gross profit came to DKK 26,958,407, and the net result was DKK 1,584,074.
About PHARMACEUTICAL RESEARCH ASSOCIATES DENMARK ApS
PHARMACEUTICAL RESEARCH ASSOCIATES DENMARK ApS is a Danish company of the type Anpartsselskab based in Hellerup, founded in 2010. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Thomas Noel O´Leary. The board consists of Thomas Noel O´Leary (chair), John Sheahan and Simon Peter Hollywood. The company is owned by ICON CLINICAL (UK) LIMITED. The company has 49 employees (2026). In 2025, the company reported a gross profit of DKK 61,634,124 and a net result of DKK 3,053,580 compared with DKK 3,554,282 the year before. Equity in the 2025 report amounted to DKK 23,945,884.
